Thus, it is conceivable that EZH2 inhibitor can reverse EZH2-mediated repression of FOXO1 expression in both PTEN positive and negative prostate cancer cells; however, it induces substantial death only in PTEN-positive cells where FOXO1 protein is primarily located in the nucleus. Here, FOXO1 is linked to prostate carcinoma.